Next-generation complex conjugates, such as peptide conjugates, radioconjugates, ligand-conjugated antisense medicines, and small-molecule drug conjugates, are expected to outpace growth comparative antibody drug conjugates (ADCs), which are still slated for strong growth.

Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market analysis of these next-generation complex conjugates and ADCS.

Support the show

Support the show

New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have been several large deals among the bio/pharma majors and smaller innovator companies, with one drug candidate recently gaining FDA approval. What is the market potential and both the promise and limitations of these drug classes? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest insights.

Support the show

As the industry reaches the mid-point in 2026, how are CDMOs of small-molecule drugs faring? The larger scale CDMOs with late-phase and/or commercial-scale capabilities are faring well while smaller and mid-sized CDMOs specializing in early-stage development and clinical-scale capabilities are facing some headwinds from more challenging trends in biotech financing, but opportunities lie ahead. Brian Scanlan, Managing Partner, Freedom Bioscience Partners, a strategic advisory firm to CROs, CDMOs, and investors, provides the latest insights.

Support the show

Support the show

As bio/pharma companies and their suppliers set and implement their sustainability strategies, what issues top the industry’s sustainability agenda? Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026. Dr. Ute Schleyer, Vice President, Internal Project Management and EHS Sustainability, Vetter, provides key insights on how bio/pharmaceutical companies and their suppliers are collaborating and the sustainability frameworks supporting these efforts.

Support the show

In taking a 360-degree view of the CDMO market for injectables, what are the key developments from 2025 that continue to loom large in 2026? Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and lead of L.E.K.’s Pharmaceutical Contract Services Practice, provided perspectives on evolving US tariff/trade policy, a policy movement in the US to most-favored nation drug pricing, and key technology trends and what impact they may have on the CDMO market for injectabes.

Support the show

Which bio/pharmaceuticals, slated to be launched or approved in 2026, may be potential blockbusters or are raising the innovation bar to new heights? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, highlights the 11 drugs making Clarivate’s Drugs to Watch list in 2026, key trends in product innovation, and the companies and products on the industry’s radar.

Support the show